Cubist Reports First $100 Million Revenue Quarter;
Q2 2008 Total Revenues $101.8 Million;
Total Net Product Revenues $101.4 Million
07.17.08 –
GAAP Basic and Diluted Net Income of $0.03 Per Share, Reflecting One Time Expenses
Non-GAAP Basic and Diluted Net Income of $0.38 and $0.35 Per Share, Respectively
Earnings Conference Call & Webcast Today (With Slides) at 5:00 p.m. EDT
Cubist to Promote in the U.S. AstraZeneca's Broad Spectrum Antibiotic, MERREM I.V.
07.02.08 –
- Leverages Proven U.S. Acute Care Sales Organization
- Complements Cubist's Gram-Positive CUBICIN